You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
基石藥業(02616.HK)公布抑制劑聯合治療在晚期實體瘤患者中的Ib期研究初步結果
阿思達克 09-20 08:25
基石藥業-B(02616.HK)公布,在2021年歐洲腫瘤內科學會年會上公布了CS1002(抗CTLA-4單抗)與CS1003(抗PD-1單抗)聯合治療在晚期實體瘤患者中的Ib期研究(CS1002-101,NCT03523819)的初步結果。 研究數據表明,CS1002與CS1003免疫檢查點抑制劑聯合治療,在未接受過抗PD(L)1治療的微衛星高度不穩定(MSI-H)/錯配修復缺陷(dMMR)實體瘤患者與經抗PD-(L)1治療失敗的黑色素瘤患者中,均展示出了良好的安全性與令人鼓舞的抗腫瘤活性。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account